FDA panel to vote on Pfizer booster shot

A Food and Drug Administration panel will debate Friday if there’s enough proof that a booster dose of Pfizer’s COVID-19 vaccine is safe and effective — the first step toward deciding which Americans need one and when. The FDA on Wednesday posted much of the evidence its advisory panel will consider Friday. The agency struck a decidedly neutral tone on the rationale for boosters — an unusual and careful approach that’s all the more striking after President Joe Biden and his top health advisers trumpeted a booster campaign they hoped to begin by late September.